Cookies

Like most websites The Ophthalmologist uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.
Subspecialties Retina, Business and Innovation

A New Step Forward

sponsored by Alimera

Diabetic macular edema (DME) is one of the main causes of blindness globally. To address this challenge, we must have access to the best tools available – and match them to appropriate patients. One such tool is ILUVIEN® (fluocinolone acetonide intravitreal implant), indicated for the treatment of vision impairment associated with chronic diabetic macular oedema, considered insufficiently responsive to available therapies (i.e. DME that persists or recurs despite treatment). A recent conference in Rome (ILUVIEN Medical Expert User Group Meeting - an Alimera Sciences promotional meeting) on November 17, 2018 gathered international experts to discuss best practice and real-world experience with this sustained-release steroid implant.

Download the PDF here

Enjoy our FREE content!

Log in or register to gain full unlimited access to all content on the The Ophthalmologist site. It’s FREE!

Login

Or register now - it’s free!

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Ophthalmologist magazine

When you click “Register” we will email you a link, which you must click to verify the email address above and activate your account. If you do not receive this email, please contact us at [email protected].

Register to The Ophthalmologist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Ophthalmologist magazine

Register